← Leaderboards
Krishnendu Roy
University Of Texas Austin
$9,091,105
Attributed
$11,796,332
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,996,332 · 8
FDA$1,800,000 · 1
By mechanism
R01$6,719,433 · 3
U01$3,320,578 · 1
R21$1,609,521 · 4
R03$146,800 · 1
Top collaborators
- Jyothi Rengarajan6 shared
- Joanne Kurtzberg3 shared
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsCellsT-LymphocyteBaseIn VitroMalignant NeoplasmsSignal TransductionAntigensIn VivoResponseDensityMediatingTechnologyImmune ResponseCell PhysiologyImmuneGenesLeadReportingAffectImmunityLigandsPolymersMolecular
Grant awards (30)
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$863,755
R01 · FY2024 · AI
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$90,542
R01 · FY2024 · AI
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$867,492
R01 · FY2023 · AI
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$90,542
R01 · FY2023 · AI
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$861,166
R01 · FY2022 · AI
Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy$836,957
R01 · FY2021 · AI
Data Enabled Automation for the Improved Efficiency, Yield, and Reproducibility of the Manufacturing of Human Umbilical Cord Tissue Mesenchymal Stromal Cells for Clinical Therapeutic Use$600,000
R01 · FY2020 · FD · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$519,312
U01 · FY2020 · AI · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$150,285
U01 · FY2020 · AI · contact PI
Data Enabled Automation for the Improved Efficiency, Yield, and Reproducibility of the Manufacturing of Human Umbilical Cord Tissue Mesenchymal Stromal Cells for Clinical Therapeutic Use$600,000
R01 · FY2019 · FD · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$523,574
U01 · FY2019 · AI · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$847,521
U01 · FY2018 · AI · contact PI
Data Enabled Automation for the Improved Efficiency, Yield, and Reproducibility of the Manufacturing of Human Umbilical Cord Tissue Mesenchymal Stromal Cells for Clinical Therapeutic Use$600,000
R01 · FY2018 · FD · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$731,175
U01 · FY2017 · AI · contact PI
Effect of presentation methods on the molecular mechanism of combinatorial adjuvants$548,711
U01 · FY2016 · AI · contact PI
Synthetic, Thymus-like 3D Niche for T Cell Generation from Stem Cells$213,678
R21 · FY2011 · EB · contact PI
Synthetic, Thymus-like 3D Niche for T Cell Generation from Stem Cells$186,863
R21 · FY2010 · EB · contact PI
Interactions of ES Cells with 3D Biomaterials$384,199
R01 · FY2009 · EB · contact PI
Generation of therapeutic T cells from cord blood-derived stem cells$221,250
R21 · FY2009 · HL · contact PI
Shape Specific, Enzyme-Responsive, Nano-Imprinted Particles for Drug Delivery$220,045
R21 · FY2009 · EB · contact PI
Interactions of ES Cells with 3D Biomaterials$52,934
R01 · FY2009 · EB · contact PI
Interactions of ES Cells with 3D Biomaterials$286,045
R01 · FY2008 · EB · contact PI
Shape Specific, Enzyme-Responsive, Nano-Imprinted Particles for Drug Delivery$184,770
R21 · FY2008 · EB · contact PI
Generation of therapeutic T cells from cord blood-derived stem cells$183,750
R21 · FY2008 · HL · contact PI
Interactions of ES Cells with 3D Biomaterials$291,883
R01 · FY2007 · EB · contact PI
Novel Adjuvant Formulations for Genetic Vaccines$215,077
R21 · FY2007 · AI · contact PI
Interactions of ES Cells with 3D Biomaterials$293,918
R01 · FY2006 · EB · contact PI
Novel Adjuvant Formulations for Genetic Vaccines$184,088
R21 · FY2006 · AI · contact PI
Cutaneous DNA immunization with polymer-nanoparticles$73,400
R03 · FY2003 · AI
Cutaneous DNA immunization with polymer-nanoparticles$73,400
R03 · FY2002 · AI